Similarly, Bardia et al. [46] found that combining radiomic phenotypes, clinical variables, and circulating tumor DNA (ctDNA), enhanced prediction of EGFR-targeted therapy outcomes for NSCLC. This evidence concerns the gene EGFR and neoplasm.